PF-956980|PF 956980;PF956980

Cas No.:	1262832-74-5
Chemical Name:	{(3R,4R)-4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-pyrrolidin-1-yl-methanone
Synonyms:	PF 956980;PF956980
SMILES:	C(N1CC[C@H](C)[C@H](N(C)C2N=CN=C3NC=CC3=2)C1)(N1CCCC1)=O
Formula:	C₁₈H₂₆N₆O
M.Wt:	342.44
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:

A potent, highly specific JAK3 inhibitor with IC50 of 4 nM; shows only modest inhibition of PKA (6.7 uM) and LCK (10.9 uM) in vitro; selectively downregulates JAK2 and JAK3 mRNA, corresponding to changes observed at the protein level; shows in vivo activity consistent with in vitro enzyme and whole blood assays (39 ng/ml); dose-dependently inhibits the DTH response in mice with EC50 of 5 mg/kg.

MSDS

COA

LOT NO.	DOWNLOAD

2018-0101

Cat. No.	Product name	Field of application
DC47590	Ten01	Ten01 has 5.0 nM activity against JAK1 kinase.
DC47041	Lorpucitinib	Lorpucitinib is a Gut-Restricted JAK Inhibitor for the research of Inflammatory Bowel Disease.
DC47039	Itacnosertib	Itacnosertib (TP-0184) is both inhibitor to JAK2, ACVR1 (ALK2) and ALK5 as described in WO2014151871.
DC47030	Ilunocitinib	Ilunocitinib (compound 27) is a JAK inhibitor (extracted from patent WO2009114512A1).
DC46857	Nezulcitinib	Nezulcitinib (TD-0903) is an inhaled and lung-selective pan-Janus kinase (JAK) inhibitor. Nezulcitinib can be used for the research of COVID-19 associated acute lung injury and impaired oxygenation.
DC46856	JAK2/FLT3-IN-1 TFA	JAK2/FLT3-IN-1 (TFA) is a potent and orally active dual JAK2/FLT3 inhibitor with IC50 values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2, FLT3, JAK1 and JAK3, respectively. JAK2/FLT3-IN-1 (TFA) has anti-cancer activity.
DC46855	Deuruxolitinib	Deuruxolitinib (CTP-543), a deuterated Ruxolitinib, modulates the activity of JAK1/JAK2. Deuruxolitinib can be used for the research hair loss disorders (from patent WO2017192905A1, compound I).
DC44160	JAK2/FLT3-IN-1	JAK2/FLT3-IN-1 is a potent and orally active dual JAK2/FLT3 inhibitor with IC50 values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2, FLT3, JAK1 and JAK3, respectively. JAK2/FLT3-IN-1 has anti-cancer activity.
DC42325	(3S,4S)-Tofacitinib	(3S,4S)-Tofacitinib is the less active S-enantiomer of Tofacitinib. Tofacitinib inhibits JAK3 with IC50 of 1 nM.
DC42324	JAK2-IN-7	JAK2-IN-7 is a selective JAK2 with IC50s of 3, 11.7, and 41 nM for JAK2, SET-2, and Ba/F3V617F cells. JAK2-IN-7 possesses >14-fold selectivity over JAK1, JAK3, FLT3. JAK2-IN-7 stimulates cell cycle arrest in the G0/G1 phase and induces tumor cellapoptosis. Antitumor activities.